As the healthcare paradigm continues to shift in the US, gastroenterology as a specialty is facing many of the same challenges and obstacles that the rest of the medical community is coming to grips with. As the delivery and reimbursement of health care becomes more value based, invasive and expensive methods of diagnosis like colonoscopies and endoscopies are receiving lower reimbursements and increasingly substituted or supplemented with less costly and less invasive specialty diagnostics. At the same time, patient needs and expectations for comprehensive care, information and monitoring, and symptom management are increasing. One of the leading challenges for gastroenterologists today is setting themselves apart by creating value and delivering quality services to their patients in a timely and cost-efficient manner. It is your ability to provide complete, accurate, and thorough care for patients with gastrointestinal conditions, which distinguishes gastroenterologists from other physicians that provide some similar services.

At CDI, we want to provide you with the most reliable and highest quality clinical data to guide your diagnostic and treatment decisions using a patient-and-provider centric model. Our team has decades of combined experience offering hydrogen and methane breath testing products, services, and solutions for diagnosing small intestinal bacterial overgrowth (SIBO) and other carbohydrate malabsorption disorders to providers and patients at an affordable cost, putting the patient first and allowing them to take the tests in the comfort of their own homes. This alleviates the burden on the patient’s schedule, minimizes overhead and costly equipment purchases, and frees up valuable resources in your practice. Working with CDI’s breath testing portfolio, supported by our newly constructed state-of-the-art laboratory in Salem, Massachusetts puts you and your practice at the forefront of accessible and reliable functional gastrointestinal diagnostics. Recently the North American Consensus on hydrogen methane based testing was published based on the consensus of 17 world renown clinician scientists, many of whom serve on CDI’s medical advisory board and are familiar with our service model, quality standards, and laboratory staff. CDI is the first laboratory to incorporate these important consensus standards into the modern-day healthcare delivery of hydrogen and methane breath testing.

CDI also offers a first-of-its-kind proprietary blood test for irritable bowel syndrome (IBS-D/M) commercially available in international markets as IBSchek®. Millions of patients afflicted with irritable bowel syndrome can now be diagnosed quickly and accurately with this simple blood test. The antibodies, anti-CdtB and anti-vinculin, discovered and developed by a team of world-leading researchers at Cedars-Sinai Medical Center led by Dr. Mark Pimentel, are shedding new light on a disease state that has historically been a 4-6 year diagnostic pathway of excluding other conditions. IBSchek may circumvent the tangled and expensive web of exclusionary testing that cost your patients valuable time and quality of life.

The type of diagnostic approach you take for your patients depends on each individual patient case, and we know that the accuracy and speed with which data is delivered to you to guide that approach is critical to your ability to be effective. CDI has the tools to give you the important clinical data that both you and your patients are looking for, and CDI will deliver our services in the most convenient, customer-centric, and effective manner available.

Am J Gastroenterol 2017; 112:775–784; doi: 10.1038/ajg.2017.46; published online 21 March 2017